Remedium Bio, a pioneering genetic medicine company, has announced a multi-target research and development collaboration with Eli Lilly and Company to create new gene therapies for Type 2 diabetes and obesity. The partnership will leverage Lilly's extensive expertise in metabolic diseases and Remedium's proprietary Prometheus™ gene therapy platform. This platform is unique because it allows for a single, subcutaneously administered injection to deliver long-lasting, dose-adjustable therapeutic effects. The goal is to develop one-time treatments that can provide tunable control of therapeutic protein expression with multi-year efficacy, offering a significant change from the current need for frequent protein-based injections.

Under the terms of the agreement, Remedium will receive an upfront payment and an equity investment from Lilly. The company is also eligible to receive potential development and commercialization milestone payments, along with tiered royalties on any future product sales. According to Frank Luppino, the CEO of Remedium Bio, this collaboration not only validates the potential of the Prometheus™ platform but also expands its reach into one of the world's largest therapeutic markets. The company believes this technology can transform the patient experience for those living with Type 2 diabetes and obesity by providing a simpler, more durable, and more cost-effective treatment option. Remedium is based in Lilly Gateway Labs in Boston, which is part of Lilly's Catalyze360™ model, demonstrating a close and strategic relationship from the outset.